Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer.

Sun T, Du SY, Armenia J, Qu F, Fan J, Wang X, Fei T, Komura K, Liu SX, Lee GM, Kantoff PW.

Oncogenesis. 2018 Mar 13;7(3):30. doi: 10.1038/s41389-018-0039-5.

2.

Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts.

Knuuttila M, Mehmood A, Huhtaniemi R, Yatkin E, Häkkinen MR, Oksala R, Laajala TD, Ryberg H, Handelsman DJ, Aittokallio T, Auriola S, Ohlsson C, Laiho A, Elo LL, Sipilä P, Mäkelä SI, Poutanen M.

Am J Pathol. 2018 Jan;188(1):216-228. doi: 10.1016/j.ajpath.2017.08.036. Epub 2017 Nov 7.

PMID:
29126837
3.

The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.

Wilson S, Fan L, Sahgal N, Qi J, Filipp FV.

Oncotarget. 2017 May 2;8(18):30328-30343. doi: 10.18632/oncotarget.15681.

4.

Crucial role of estrogen for the mammalian female in regulating semen coagulation and liquefaction in vivo.

Li S, Garcia M, Gewiss RL, Winuthayanon W.

PLoS Genet. 2017 Apr 17;13(4):e1006743. doi: 10.1371/journal.pgen.1006743. eCollection 2017 Apr.

5.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

6.
7.

An efficient method for native protein purification in the selected range from prostate cancer tissue digests.

Ahmad R, Nicora CD, Shukla AK, Smith RD, Qian WJ, Liu AY.

Chin Clin Oncol. 2016 Dec;5(6):78. doi: 10.21037/cco.2016.12.03.

8.

Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.

Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.

Anticancer Res. 2017 Jan;37(1):125-134.

PMID:
28011482
9.

Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia.

Li K, Gesang L, Dan Z, Gusang L.

Int J Mol Med. 2017 Feb;39(2):287-296. doi: 10.3892/ijmm.2016.2830. Epub 2016 Dec 14.

10.

Urological cancer related to familial syndromes.

Costa WH, Jabboure G Netto, Cunha IW.

Int Braz J Urol. 2017 Mar-Apr;43(2):192-201. doi: 10.1590/S1677-5538.IBJU.2016.0125. Review.

11.

TET2 binds the androgen receptor and loss is associated with prostate cancer.

Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, Bouk AJ, Butcher D, Wang Z, Sun L, Misner K, Tan W, Esnakula A, Esposito D, Huang WY, Hoover RN, Tucker MA, Keller JR, Boland J, Brown K, Anderson SK, Moore LE, Isaacs WB, Chanock SJ, Yeager M, Dean M, Andresson T.

Oncogene. 2017 Apr;36(15):2172-2183. doi: 10.1038/onc.2016.376. Epub 2016 Nov 7.

12.

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.

Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.

Prostate. 2016 Dec;76(16):1536-1545. doi: 10.1002/pros.23238. Epub 2016 Jul 30.

PMID:
27473672
14.

IGFBP3 and MAPK/ERK signaling mediates melatonin-induced antitumor activity in prostate cancer.

Mayo JC, Hevia D, Quiros-Gonzalez I, Rodriguez-Garcia A, Gonzalez-Menendez P, Cepas V, Gonzalez-Pola I, Sainz RM.

J Pineal Res. 2017 Jan;62(1). doi: 10.1111/jpi.12373. Epub 2016 Nov 9.

PMID:
27736013
15.

Frequency of KLK3 gene deletions in the general population.

Rodriguez S, Al-Ghamdi OA, Guthrie PA, Shihab HA, McArdle W, Gaunt T, Alharbi KK, Day IN.

Ann Clin Biochem. 2017 Jul;54(4):472-480. doi: 10.1177/0004563216666999. Epub 2016 Aug 23.

16.

Evaluation of a subset of tumor suppressor gene for copy number and epigenitic changes in pleomorphic adenoma and carcinoma ex-pleomorphic adenoma carcinogenesis.

Mariano FV, Egal ES, Pramio D, Fidalgo F, Sara É, Costa AF, de Oliveira Gondak R, Coletta RD, de Almeida OP, Kowalski LP, Victorino Krepischi AC, Altemani A.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Sep;122(3):322-31. doi: 10.1016/j.oooo.2016.05.002. Epub 2016 May 24.

PMID:
27544395
17.

Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.

Ylitalo EB, Thysell E, Jernberg E, Lundholm M, Crnalic S, Egevad L, Stattin P, Widmark A, Bergh A, Wikström P.

Eur Urol. 2017 May;71(5):776-787. doi: 10.1016/j.eururo.2016.07.033. Epub 2016 Aug 3.

18.

Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.

Olsen JR, Azeem W, Hellem MR, Marvyin K, Hua Y, Qu Y, Li L, Lin B, Ke X, Øyan AM, Kalland K.

BMC Cancer. 2016 Jul 4;16:377. doi: 10.1186/s12885-016-2453-4.

19.

Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.

Alvarez-Cubero MJ, Pascual-Geler M, Martinez-Gonzalez LJ, Expósito Ruiz M, Saiz M, Cozar JM, Lorente JA.

Urol Oncol. 2016 Oct;34(10):431.e1-8. doi: 10.1016/j.urolonc.2016.05.018. Epub 2016 Jun 16.

PMID:
27318894
20.

Systematic meta-analyses of gene-specific genetic association studies in prostate cancer.

Hao Q, Wei D, Zhang Y, Chen X, Yang F, Yang Z, Zhu X, Wang J.

Oncotarget. 2016 Apr 19;7(16):22271-84. doi: 10.18632/oncotarget.7926.

Supplemental Content

Loading ...
Support Center